Video

Dr. Raez on State of Lung Cancer Treatment in Light of COVID-19

Author(s):

Luis E. Raez, MD

Luis E. Raez, MD, discusses how the COVID-19 pandemic has impacted the treatment of patients with lung cancer.

Luis E. Raez, MD, medical director of Memorial Cancer Institute, and chief of Hematology/Oncology at Memorial Healthcare System, to discuss how the COVID-19 pandemic has impacted the treatment of patients with lung cancer.

Please visit www.OncLive.com to watch the entitreity of the MJH Life Sciences News Network, which provides the latest news across a variety of healthcare specialties, and a number of interviews with experts in the medical field, many of which are focused on the ongoing COVID-19 pandemic.

Related Videos
Abdul Rafeh Naqash, MD
Priya U. Kumthekar, MD
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Related Content
Updates and Advances in Early Stage Breast Cancer
April 5th 2023

Updates and Advances in Early Stage Breast Cancer

Manali Kamdar, MD
December 11th 2021

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL

Brandon Blue, MD
October 1st 2021

Dr. Blue on the Utility of Carfilzomib in Relapsed/Refractory Multiple Myeloma

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma
July 29th 2020

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma
June 11th 2020

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer
June 2nd 2020

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer